Cefepime and Zidebactam
Brand names: Zaynich · Active ingredient: Zidebactam Dihydrate, Cefepime Hydrochloride
In short: ZAYNICH is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacaecomplex, and Pseudomonas aeruginosa.
What is Cefepime and Zidebactam used for?
ZAYNICH is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms:
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacaecomplex, and
Pseudomonas aeruginosa.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZAYNICH and other antibacterial drugs, ZAYNICH should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Cefepime and Zidebactam dosage
The recommended dosage of ZAYNICH is 3 grams (2 grams cefepime and 1 gram zidebactam) administered every 8 hours by intravenous (IV) infusion over 1 hour in adult patients with an eGFR greater than or equal to 60 mL/min.
The duration of treatment is 7 days to 10 days.
Table 1shows the recommended intravenous dosage of ZAYNICH for patients with varying degrees of renal function. Dosage adjustment of ZAYNICH is recommended in adult patients with renal impairment who have an eGFR of less than 60 mL/min, including patients receiving intermittent hemodialysis (IHD) . The duration of treatment is 7 days to 10 days.
Administer each intravenous infusion over 1 hour.
eGFR
As calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) formula.
(mL/min) | Dose
The total duration of treatment is for 7 to 10 days. | Dosing Interval
60 to 89 | ZAYNICH 3 grams
Provides 2 grams cefepime and 1 gram zidebactam. | Every 8 hours
30 to 59 | ZAYNICH 1.5 grams
Provides 1 gram cefepime and 0.5 grams zidebactam. | Every 8 hours
15 to 29 | ZAYNICH 1.5 grams | Every 12 hours
8 to 14 (with or without IHD)
On hemodialysis days, recommended dose should be administered after a hemodialysis session. On days, when hemodialysis is not performed, administer 24 hours after the previous dose. | ZAYNICH 1.5 grams | Every 24 hours
Preparation
ZAYNICH is supplied as a sterile dry powder in a single-dose vial that must be reconstituted and further diluted prior to intravenous infusion as outlined below. ZAYNICH does not contain preservatives. Aseptic techniques must be used for reconstitution and dilution. Prepare the required dose for intravenous infusion using the steps described below:
1. Reconstitute the powder in the ZAYNICH vial with 10 mL of 0.9% Sodium Chloride Injection, or 5% Dextrose Injection, or Lactated Ringer's solution from a 100 mL infusion bag or with 10 mL of sterile Water for Injection.
2. Mix gently to dissolve the content. The reconstituted ZAYNICH solution will have a resultant concentration of approximately 240 mg/mL. The final volume is approximately 13 mL.
3. The reconstituted ZAYNICH solution is
notfor direct injection and must be further diluted, prior to administration as described in Step 4 below.
4. The reconstituted solution should be used immediately after preparation or within the stability period, as described below:
5. The reconstituted ZAYNICH solution can be stored for up to 6 hours at 20°C to 25°C (68°F to 77°F) or up to 12 hours at 2°C to 8°C (36°F to 46°F). After reconstitution, retain the vial in the outer carton to protect it from light.
6. The reconstituted solution must be diluted further in the 100 mL infusion bag used in Step 1. …
How to take Cefepime and Zidebactam — instructions & advice from the label
Serious Allergic Reactions
Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. Advise patients to discontinue ZAYNICH and seek immediate medical attention if allergic reactions occur
.
Neurotoxicity
Advise patients of neurological adverse reactions that could occur with ZAYNICH use. Instruct patients or their caregivers to inform their healthcare provider at once of any neurological signs and symptoms, including encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia (disturbance of speaking and understanding spoken and written language), myoclonus, seizures and nonconvulsive status epilepticus
.
Potentially Serious Diarrhea
Diarrhea is a common problem caused by antibacterial drugs, which usually ends when the antibacterial drug is discontinued. Inform patients that they may develop watery and bloody stools (with or without stomach cramps and fever) during treatment and as late as two or more months after having taken the last dose of the antibacterial drug. …
Warnings & precautions
Do not take this medicine if: ZAYNICH is contraindicated in patients with a known history of serious hypersensitivity to the components of ZAYNICH (cefepime and zidebactam) or other beta-lactam antibacterial drugs .
Serious hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with ZAYNICH. Serious and occasionally fatal hypersensitivity reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs .
Before therapy with ZAYNICH is instituted, carefully inquire about previous hypersensitivity reactions to cefepime, cephalosporins, penicillins, or other beta-lactams because cross-hypersensitivity among beta-lactam antibacterial drugs has been reported. If an allergic reaction to ZAYNICH occurs, discontinue the drug and institute appropriate supportive measures.
Neurotoxicity has been reported during treatment with cefepime, a component of ZAYNICH, including life threatening or fatal occurrences of the following: encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus
. Most cases occurred in patients with renal impairment who did not receive appropriate dosage adjustment. However, some cases of neurotoxicity occurred in patients receiving a dosage adjustment appropriate for their degree of renal impairment. In the majority of cases, symptoms of neurotoxicity were reversible and resolved after discontinuation of cefepime and/or after hemodialysis. If neurotoxicity associated with ZAYNICH therapy occurs, discontinue ZAYNICH and institute appropriate supportive measures.
Clostridioides difficile
(C. difficile)infection (CDI) has been reported with the use of nearly all antibacterial agents including ZAYNICH and may range in severity from mild diarrhea to fatal colitis. …
Cefepime and Zidebactam side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypersensitivity Reactions
Neurotoxicity
Clostridiodes difficileInfection
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
ZAYNICH was evaluated in a phase 3 study in patients with cUTI, including pyelonephritis (also referred to as Trial 1), which included 352 patients treated with ZAYNICH 3 grams (2 grams cefepime and 1 gram zidebactam) every 8 hours infused over 1 hour, and 177 patients treated with the comparator, meropenem, 1 gram every 8 hours, infused over 30 minutes. Patients received treatment for 7 to 10 days. The median duration of therapy was 8 days in both treatment groups in the safety analysis set.
The mean age of patients treated with ZAYNICH was 65 years and 61% of patients were 65 years of age or older. Patients were predominantly male (56%) and White (88%).
Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation
Treatment was discontinued due to adverse reactions in 1.4% (5/352) of patients receiving ZAYNICH and in 1.1% (2/177) of patients receiving meropenem. The adverse reactions resulting in discontinuation of ZAYNICH were anaphylactic reaction,
C. …
Drug interactions
Monitor renal function if aminoglycosides are to be administered with ZAYNICH because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.
Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function when ZAYNICH is concomitantly administered with potent diuretics.
The administration of ZAYNICH may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
About this medicine
ZAYNICH for injection contains cefepime hydrochloride, a cephalosporin antibacterial drug, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial.
Cefepime, present as cefepime hydrochloride monohydrate, is a white to pale yellow powder. The chemical name for cefepime hydrochloride monohydrate is 1-[[(6
R,7
R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium chloride,7
2-(
Z)-(
O-methyloxime), monohydrochloride, monohydrate, which corresponds to the following structural formula:
Figure 1. Cefepime Hydrochloride
The molecular formula of cefepime hydrochloride monohydrate is C
19H
25ClN
6O
5S
2·HCl·H
2O and the molecular weight is 571.56.
Zidebactam is a white to pale yellow powder. The chemical name of zidebactam is (2
S,5
R)-7-Oxo-6-sulphooxy-2-[
N'-((
R)-piperidin-3-carbonyl)hydrazinocarbonyl]-1,6-diazabicyclo[3.2.1]octane, dihydrate, which corresponds to the following structural formula:
Figure 2. Zidebactam
Zidebactam is freely soluble in water. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c84e652e-5e76-4568-8812-bd5fa34803b6. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin